Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition

Abstract ERK5 has emerged as a promising therapeutic target in cancer treatment due to its pivotal role in regulating tumor cell proliferation and survival. In this study, we synthesized novel derivatives of 1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt (NAIMS), assessed their binding a...

Full description

Saved in:
Bibliographic Details
Main Authors: Haena Lee, Anh-Thu Nguyen, Hyunkyung Choi, Ki-Young Kim, Hakwon Kim
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-96306-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849713532307767296
author Haena Lee
Anh-Thu Nguyen
Hyunkyung Choi
Ki-Young Kim
Hakwon Kim
author_facet Haena Lee
Anh-Thu Nguyen
Hyunkyung Choi
Ki-Young Kim
Hakwon Kim
author_sort Haena Lee
collection DOAJ
description Abstract ERK5 has emerged as a promising therapeutic target in cancer treatment due to its pivotal role in regulating tumor cell proliferation and survival. In this study, we synthesized novel derivatives of 1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt (NAIMS), assessed their binding affinity with the ERK5 protein through molecular modeling, and evaluated their anti-cancer activity through the ERK5 kinase assay. Based on the MTT assay and qRT-PCR analysis of 21 synthesized NAIMS, the IC50 values for 4c, 4e, and 4k (8.5 μM, 6.8 μM, and 8.9 μM, respectively) and the inhibition rate of the expression of PCNA for 4c, 4e, and 4k (50%, 61.1%, and 70.2% of 5 μM respectively) were chosen for comprehensive biological research. Further analyses including DAPI staining, and flow cytometry confirmed that 4c, 4e, and 4k induced late-stage apoptosis, and triggered cell cycle arrest in the G2/M phase of HeLa cells. Moreover, molecular modeling analysis showed that 4e exhibited strong and stable molecular interactions at the ERK5 ATP-binding site. Our results strongly suggest that NAIMS compounds, especially 4e, could serve as novel inhibitors of ERK5, presenting promising lead compound to develop for cancer treatment.
format Article
id doaj-art-478b932aa471464f8cd30b4b9f3fb45a
institution DOAJ
issn 2045-2322
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-478b932aa471464f8cd30b4b9f3fb45a2025-08-20T03:13:57ZengNature PortfolioScientific Reports2045-23222025-04-0115111610.1038/s41598-025-96306-xAnti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibitionHaena Lee0Anh-Thu Nguyen1Hyunkyung Choi2Ki-Young Kim3Hakwon Kim4Department of Applied Chemistry, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee UniversityDepartment of Genetics and Biotechnology, College of Life Science, Graduate School of Biotechnology, Kyung Hee UniversityDivision of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea UniversityDepartment of Genetics and Biotechnology, College of Life Science, Graduate School of Biotechnology, Kyung Hee UniversityDepartment of Applied Chemistry, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee UniversityAbstract ERK5 has emerged as a promising therapeutic target in cancer treatment due to its pivotal role in regulating tumor cell proliferation and survival. In this study, we synthesized novel derivatives of 1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt (NAIMS), assessed their binding affinity with the ERK5 protein through molecular modeling, and evaluated their anti-cancer activity through the ERK5 kinase assay. Based on the MTT assay and qRT-PCR analysis of 21 synthesized NAIMS, the IC50 values for 4c, 4e, and 4k (8.5 μM, 6.8 μM, and 8.9 μM, respectively) and the inhibition rate of the expression of PCNA for 4c, 4e, and 4k (50%, 61.1%, and 70.2% of 5 μM respectively) were chosen for comprehensive biological research. Further analyses including DAPI staining, and flow cytometry confirmed that 4c, 4e, and 4k induced late-stage apoptosis, and triggered cell cycle arrest in the G2/M phase of HeLa cells. Moreover, molecular modeling analysis showed that 4e exhibited strong and stable molecular interactions at the ERK5 ATP-binding site. Our results strongly suggest that NAIMS compounds, especially 4e, could serve as novel inhibitors of ERK5, presenting promising lead compound to develop for cancer treatment.https://doi.org/10.1038/s41598-025-96306-xERK5 kinase1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt derivatives (NAIMS)Anti-cancerMolecular modeling
spellingShingle Haena Lee
Anh-Thu Nguyen
Hyunkyung Choi
Ki-Young Kim
Hakwon Kim
Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
Scientific Reports
ERK5 kinase
1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt derivatives (NAIMS)
Anti-cancer
Molecular modeling
title Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
title_full Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
title_fullStr Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
title_full_unstemmed Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
title_short Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition
title_sort anti cancer effects of 1 4 dialkoxynaphthalene imidazolium salt derivatives through erk5 kinase activity inhibition
topic ERK5 kinase
1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt derivatives (NAIMS)
Anti-cancer
Molecular modeling
url https://doi.org/10.1038/s41598-025-96306-x
work_keys_str_mv AT haenalee anticancereffectsof14dialkoxynaphthaleneimidazoliumsaltderivativesthrougherk5kinaseactivityinhibition
AT anhthunguyen anticancereffectsof14dialkoxynaphthaleneimidazoliumsaltderivativesthrougherk5kinaseactivityinhibition
AT hyunkyungchoi anticancereffectsof14dialkoxynaphthaleneimidazoliumsaltderivativesthrougherk5kinaseactivityinhibition
AT kiyoungkim anticancereffectsof14dialkoxynaphthaleneimidazoliumsaltderivativesthrougherk5kinaseactivityinhibition
AT hakwonkim anticancereffectsof14dialkoxynaphthaleneimidazoliumsaltderivativesthrougherk5kinaseactivityinhibition